DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases

Information source: UNC Lineberger Comprehensive Cancer Center
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: HER-2 Positive Breast Cancer

Intervention: Everolimus (Drug); Vinorelbine (Drug); Trastuzumab (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: UNC Lineberger Comprehensive Cancer Center

Official(s) and/or principal investigator(s):
Carey K Anders, MD, Principal Investigator, Affiliation: UNC Lineberger Comprehensive Cancer Center

Overall contact:
Dale Flowers, RN, Phone: (919) 966-7359, Email: dale_flowers@med.unc.edu

Summary

Purpose: This study is a single-arm, open-label phase II clinical trial testing the hypothesis that daily everolimus plus weekly vinorelbine and trastuzumab will be effective, safe, and tolerable among patients with HER2-positive breast cancer brain metastases. Once enrolled, patients will receive everolimus PO daily in combination with weekly intravenous (IV) vinorelbine and trastuzumab. Cycles will be repeated every 3 weeks (21 days). At the time of progression, patients will come off study. Participants: Up to 35 adults over 21 with HER-2 positive breast cancer that has metastasized to the brain.

Clinical Details

Official title: A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: intracranial response rate- modified RECIST Criteria

Secondary outcome:

Intracranial Response Rate- MacDonald Criteria

Extracranial response

Toxicity

Detailed description:

STUDY OBJECTIVES Primary Objective - To determine the intracranial objective response rate of

mTOR inhibition (everolimus) in combination with vinorelbine and trastuzumab in the treatment of HER2-positive, progressive breast cancer brain metastases as defined via modified RECIST criteria. Secondary Objectives

- To determine the intracranial objective response rate of mTOR inhibition (everolimus)

in combination with vinorelbine and trastuzumab in the treatment of HER2-positive, progressive breast cancer brain metastases as defined by MacDonald criteria.

- To evaluate the safety and tolerability of everolimus in combination with trastuzumab

and vinorelbine as assessed via the NCI CTCAE version 4. 0

- To evaluate time to intracranial progression after administration of everolimus in

combination with trastuzumab and vinorelbine as defined via modified RECIST criteria

- To evaluate the extracranial objective response rate as determined by RECIST 1. 1

criteria after administration of everolimus in combination with trastuzumab and vinorelbine.

- To evaluate the extracranial time to progression as determined by RECIST 1. 1 criteria

after administration of everolimus in combination with trastuzumab and vinorelbine.

- To evaluate progression free survival (PFS) and overall survival (OS) after

administration of everolimus in combination with trastuzumab and vinorelbine.

- To evaluate the impact of everolimus in combination with trastuzumab and vinorelbine on

quality of life as measured by the FACT-B and FACT-Br questionnaires. Exploratory Objective

- To evaluate biomarkers in archival tumor tissue samples and correlate with therapeutic

response to everolimus in combination with vinorelbine and trastuzumab. Following Hepatitis B antiviral prophylaxis if required, or following screening and informed consent if antiviral therapy is not needed, treatment will be initiated with everolimus PO daily in combination with weekly intravenous (IV) vinorelbine and trastuzumab (Days 1, 8, and 15) A cycle is defined as 3 weeks (21 days). Cycles of therapy will be repeated until documented disease progression, unacceptable toxicity, or patient withdrawal from study for other reasons, including death.

Eligibility

Minimum age: 21 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria

- Histologically-confirmed HER2-positive (IHC 3+ or fluorescence in situ hybridization

[FISH] amplified; by clinical assay on either primary or metastatic tumor) adenocarcinoma of the breast with at least one progressive and/or new metastatic brain lesion (>/=5 mm on radiographic imaging) after receipt of intracranial radiation therapy (whole brain radiation therapy, stereotactic radiosurgery, gamma knife, or equivalent). Patients in whom BM are asymptomatic and detected during routine brain MRI screening per institutional protocols are eligible.

- Prior intracranial radiation therapy (whole brain radiation therapy, stereotactic

radiosurgery, gamma knife or equivalent) is allowed but not required.

- Patients with no prior treatment with ICR may be included unless ICR is emergently

indicated (in consultation with a local therapist, ie neurosurgeon or radiation oncologist)

- ECOG performance status of 0-2.

- Life expectancy >12 weeks.

- At least 21 years of age.

- No prior mTOR inhibitors

- Prior navelbine allowed provided navelbine therapy discontinued >/= 12 months from

Day 1 of treatment under this protocol.

- Last anti-cancer treatment (including any investigational drug) >/= 2 weeks from

initiation of protocol based therapy, provided all AEs (other than alopecia) have resolved to ≤grade 1 at baseline.

- No active serious infection or other comorbid illness which would impair ability to

participate in the trial.

- Left ventricular ejection fraction assessment (echocardiogram or MUGA scan) performed

within 4 weeks prior to study initiation, showing a LVEF value ≥ lower limit of normal (LLN).

- If patient is on dexamethasone, must be on stable or decreasing dose of dexamethasone

for ≥7 days. If patient is on different glucocorticoid e. g., prednisone, must be converted to dexamethasone prior to enrollment. Refer to dose modification of everolimus for patients taking dexamethasone.

- Interval ≥4 weeks between open brain biopsy and initiation of protocol-based therapy.

- INR ≤2. 0. Anticoagulation is allowed if target INR ≤2. 0 on a stable dose of warfarin

or if patient on a stable dose of LMW heparin for >1 weeks at time of enrollment.

- Fasting serum cholesterol ≤300 mg/dL OR ≤7. 75 mmol/L AND fasting triglycerides ≤2. 5 x

ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.

- Patients must have adequate organ function as evidenced by:

- Absolute neutrophil count ≥1. 5/µL

- Platelet count ≥100,000/µL

- Hg ≥9 g/dL

- Bilirubin ≤1. 5 x upper limit of normal (ULN)

- AST or ALT ≤2. 5 x ULN (≤5 x ULN if liver metastases are present)

- Serum creatinine ≤1. 5 x ULN

- Archived, paraffin-embedded tissue block (primary or metastatic) available for

genomic studies is required.

- Signed, IRB-approved written informed consent.

Exclusion Criteria

- Patients who have received prior treatment with an mTOR inhibitor (e. g., sirolimus,

temsirolimus, everolimus); patients who have received prior treatment with navelbine within prior 12 months.

- patients with a known hypersensitivity to everolimus or other rapamycins (e. g.

sirolimus, temsirolimus) or to its excipients.

- Patients requiring treatment with any other systemic glucocorticoid. NOTE: This

restriction regarding choice of glucocorticoid does not apply should patient need <2 week course of glucocorticoid for treatment of non-infectious pneumonitis during study (see section 4. 5.2).

- Patients with a known hypersensitivity to vinorelbine or to its excipients.

- Prior allergic reaction to trastuzumab for the treatment of metastatic breast cancer.

- Concurrent or planned radiation, hormonal, chemotherapeutic, experimental or targeted

biologic therapy.

- Peripheral neuropathy ≥grade 3.

- Evidence of frank hemorrhage or impending herniation on baseline brain imaging. NOTE:

asymptomatic micro-hemorrhage is allowed.

- Evidence of diffuse leptomeningeal disease on brain MRI or by previously documented

CSF cytology. NOTE: discrete dural metastases are permitted.

- Active cardiac disease including any of the following:

- Angina pectoris that requires the use of anti-anginal medication;

- Ventricular arrhythmias except for benign premature ventricular

contractions;

- Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled

with medication;

- Conduction abnormality requiring a pacemaker;

- Valvular disease with documented compromise in cardiac function;

- Symptomatic pericarditis

- History of cardiac dysfunction including any one of the following:

- Myocardial infarction documented by elevated cardiac enzymes or persistent

regional wall abnormalities on assessment of LV function;

- History of documented congestive heart failure (New York Heart Association

functional classification III-IV);

- Documented cardiomyopathy

- Patients who have had a major surgery or significant traumatic injury within 4 weeks

of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study.

- Patients should not receive immunization with attenuated live vaccines within 1 week

of study entry or during study period. Close contact with those who have received attenuated live vaccines should be avoided during treatment with everolimus. Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines.

- Other malignancies within the past 3 years except for adequately treated carcinoma of

the cervix or basal or squamous cell carcinomas of the skin.

- Patients who have any severe and/or uncontrolled medical conditions or other

conditions that could affect their participation in the study such as:

- severely impaired lung function, defined as spirometry and diffusion lung

capacity for carbon monoxide (DLCO) that is 50% of the normal predicted value and/or 02 saturation that is ≤88% at rest on room air

- uncontrolled diabetes, defined as fasting serum glucose >1. 5 x ULN (Note:

Optimal glycemic control should be achieved before starting trial therapy)

- active (acute or chronic) or uncontrolled severe infections

- liver disease such as cirrhosis or severe hepatic impairment (Child-Pugh class

C). Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV DNA and HCV RNA PCR testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection.

- A known history of HIV seropositivity.

- Impairment of gastrointestinal function or gastrointestinal disease that may

significantly alter the absorption of everolimus (e. g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection).

- Patients with an active, bleeding diathesis or on oral anti-vitamin K medication

(except low-dose warfarin and aspirin or equivalent, as long as the INR ≤2. 0).

- Unable or unwilling to discontinue use of prohibited fruit (or its juices) and

prohibited medications listed in Appendices II and III for at least 14 days or 5 half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study.

- Female patients who are pregnant or breastfeeding, or adults of reproductive

potential who are not using effective birth control methods. Adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes. Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test within 7 days prior to everolimus initiation.

- Male patients whose sexual partner(s) are WOCBP who are not willing to use adequate

contraception, during the study and for 8 weeks after the end of treatment

- Contraindication to gadolinium-enhanced MRI imaging.

- Inability to comply with study and/or follow-up procedures.

- History of noncompliance to medical regimens.

Locations and Contacts

Dale Flowers, RN, Phone: (919) 966-7359, Email: dale_flowers@med.unc.edu

University Of Alabama at Birmingham, Birmingham, Alabama 35294, United States; Recruiting
Lisle Nabell, MD, Principal Investigator

MD Anderson Cancer Center- Orlando, Orlando, Florida 32806, United States; Withdrawn

University Of Chicago Medical Center, Chicago, Illinois 60637, United States; Withdrawn

UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599, United States; Recruiting
Rachel Phipps, RN
Carey K Anders, MD, Principal Investigator

Carolinas Healthcare System, Charlotte, North Carolina 28203, United States; Active, not recruiting

Kinston Medical Specialists, PA, Kinston, North Carolina 28501, United States; Withdrawn

Marion L. Shepard Cancer Center, Washington, North Carolina 27889, United States; Withdrawn

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37212, United States; Recruiting
Vandana Abramson, MD, Principal Investigator

University of Virginia, Charlottesville, Virginia 22903, United States; Withdrawn

Additional Information

Lineberger Comprehensive Cancer Center

Starting date: September 2011
Last updated: June 22, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017